IMR Press / CEOG / Volume 41 / Issue 2 / DOI: 10.12891/ceog15872014

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
The influence of mifepristone to caspase 3 expression in adenomyosis
Show Less
1 Department of Obstetrics and Gynecology, Yantai Yuhuangding Hospital, Yantai (China)
Clin. Exp. Obstet. Gynecol. 2014, 41(2), 154–157; https://doi.org/10.12891/ceog15872014
Published: 10 April 2014
Abstract

Objective: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue. Materials and Methods: Sixty patients were equally divided into four groups. Groups 1,2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases. Results: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01). Conclusion: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.
Keywords
Adenomyosis
Apoptosis
Caspase3
Mifepristone
Share
Back to top